P35.05 The Monitoring of Mutated EGFR Levels in Liquid Biopsy from Patients on EGFR-TKIs – Early Detection of NSCLC Progression

Abstract

while patients with lung metastasis showed longer OS than those without lung metastasis (36.0 months vs. 28.6 months, p¼0.038). Multivariable Cox regression analysis showed presence of liver metastasis (HR[hazard ratio]: 2.265, 95% CI [confidence interval]: 1.239-4.139, p¼0.008) and brain metastasis (HR: 1.496, 95% CI: 0.963-2.080, p¼0.043) were independent risk factors for OS, and presence of lung metastasis (HR: 0.669, 95% CI: 0.460-0.971, p¼0.034) was an independent protective factor for OS. Among patients with liver, brain or lung metastasis, patients with liver metastasis had the worst OS followed by patients with brain metastasis, while patients with lung metastasis had the best OS. Conclusion: The presence of liver and brain metastasis predicts unfavorable OS, and lung metastasis predicts favorable OS in EGFR-mutated stage IV NSCLC patients receiving icotinib as first-line setting. Our work provides insight into the prognostic value of presence of metastasis to different organs at diagnosis in EGFR-mutated stage IV NSCLC patients receiving icotinib as first-line setting, which might be helpful for disease management in stratifying patients prior to first-line icotinib treatment.